TY - JOUR
AU1 - Lim-Fat, Mary Jane
AU2 - Youssef, Gilbert C
AU3 - Touat, Mehdi
AU4 - Iorgulescu, J Bryan
AU5 - Whorral, Sydney
AU6 - Allen, Marie
AU7 - Rahman, Rifaquat
AU8 - Chukwueke, Ugonma
AU9 - McFaline-Figueroa, J Ricardo
AU1 - Nayak, Lakshmi
AU1 - Lee, Eudocia Q
AU1 - Batchelor, Tracy T
AU1 - Arnaout, Omar
AU1 - Peruzzi, Pier Paolo
AU1 - Chiocca, E Antonio
AU1 - Reardon, David A
AU1 - Meredith, David
AU1 - Santagata, Sandro
AU1 - Beroukhim, Rameen
AU2 - Bi, Wenya Linda
AU2 - Ligon, Keith L
AU2 - Wen, Patrick Y
AB - BackgroundTargeted gene NGS testing is available through many academic institutions and commercial entities and is increasingly incorporated in practice guidelines for glioblastoma (GBM). This single-center retrospective study aimed to evaluate the clinical utility of incorporating NGS results in the management of GBM patients at a clinical trials-focused academic center.MethodsWe identified 1011 consecutive adult patients with pathologically confirmed GBM (IDHwt or IDHmut) who had somatic tumor sequencing (Oncopanel, ~500 cancer gene panel) at DFCI from 2013–2019. Clinical records of all IDHwt GBM patients were reviewed to capture clinical trial enrollment and off-label targeted therapy use based on NGS results.ResultsOf the 557 IDHwt GBM patients with sequencing, 182 entered clinical trials at diagnosis (32.7%) and 213 (38.2%) entered after recurrence. Sequencing results for 130 patients (23.3%) were utilized for clinical trial enrollment for either targeted therapy indications (6.9 % upfront and 27.7% at recurrent clinical trials and 3.1% for off-label targeted therapy) or exploratory studies (55.4% upfront and 6.9% recurrent clinical trials). Median overall survival was 20.1 months with no survival difference seen between patients enrolled in clinical trials compared to those who were not, in a posthoc analysis.ConclusionsWhile NGS testing has become essential for improved molecular diagnostics, our study illustrates that targeted gene panels remain underutilized for selecting therapy in GBM-IDHwt. Targeted therapy and clinical trial design remain to be improved to help leverage the potential of NGS in clinical care.
TI - Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making
JF - Neuro-Oncology
DO - 10.1093/neuonc/noab282
DA - 2021-12-08
UR - https://www.deepdyve.com/lp/oxford-university-press/clinical-utility-of-targeted-next-generation-sequencing-assay-in-idh-8HNRsBYKg0
SP - 1140
EP - 1149
VL - 24
IS - 7
DP - DeepDyve
ER -